Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by INVENTIVA

< Previous 1 2 Next >
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
From INVENTIVA
Via GlobeNewswire
Inventiva receives $10 million milestone payment from CTTQ
From INVENTIVA
Via GlobeNewswire
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease
From INVENTIVA
Via GlobeNewswire
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors
From INVENTIVA
Via GlobeNewswire
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference
From INVENTIVA
Via GlobeNewswire
Inventiva reports 2025 First Quarter Financial Information¹
From INVENTIVA
Via GlobeNewswire
Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025
From INVENTIVA
Via GlobeNewswire
Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux
From INVENTIVA
Via GlobeNewswire
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
From INVENTIVA
Via GlobeNewswire
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025
From INVENTIVA
Via GlobeNewswire
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents
From INVENTIVA
Via GlobeNewswire
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
From INVENTIVA
Via GlobeNewswire
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
From INVENTIVA
Via GlobeNewswire
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
From INVENTIVA
Via GlobeNewswire
Inventiva reports its 2024 full year results and provides a business update
From INVENTIVA
Via GlobeNewswire
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
From INVENTIVA
Via GlobeNewswire
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
From INVENTIVA
Via GlobeNewswire
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
From INVENTIVA
Via GlobeNewswire
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
From INVENTIVA
Via GlobeNewswire
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology
From INVENTIVA
Via GlobeNewswire
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
From INVENTIVA
Via GlobeNewswire
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
From INVENTIVA
Via GlobeNewswire
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
From INVENTIVA
Via GlobeNewswire
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
From INVENTIVA
Via GlobeNewswire
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024
From INVENTIVA
Via GlobeNewswire
Inventiva reports 2024 Third Quarter Financial Information¹
From INVENTIVA
Via GlobeNewswire
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
From INVENTIVA
Via GlobeNewswire
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
From INVENTIVA
Via GlobeNewswire
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
From INVENTIVA
Via GlobeNewswire
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
From INVENTIVA
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.